SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K

Launched Sales of Arbli^™, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension

Read more at globenewswire.com